What next after RAAS blockade?
At the current time, we only have RAAS blockade and hypertension control to slow progression to ESRD. What mechanisms should be targeted to slow progression (loss of GFR) in diabetic nephropathy?
At the current time, we only have RAAS blockade and hypertension control to slow progression to ESRD. What mechanisms should be targeted to slow progression (loss of GFR) in diabetic nephropathy?
Diets may impact CKD progression in several ways. A vegetarian diet lowers colon-derived uremic toxins such as indoxyl sulfate and p-cresol (Patel, J Am Soc Nephrol (Nov) 19:488A 2008). Diets high in advanced glycosylated end products are associated with evidence of glycation of body tissues. Phosphate restriction in CKD lowers serum FGF levels. A study is proposed using a 2 x 2 factorial design to study progression ...more »
Diets may impact CKD progression in several ways. A vegetarian diet lowers colon-derived uremic toxins such as indoxyl sulfate and p-cresol (Patel, J Am Soc Nephrol (Nov) 19:488A 2008). Diets high in advanced glycosylated end products are associated with evidence of glycation of body tissues. Phosphate restriction in CKD lowers serum FGF levels. A study is proposed using a 2 x 2 factorial design to study progression of CKD in patients eating a vegetarian vs. meat-based diet, with or without restriction of phosphate and high-AGE foods. Outcomes would be 50% reduction of cystatin-estimated GFR or progression to dialysis/transplantation.
« less full details »
Recent single-center randomized trials suggest reducing uric acid levels to be simultaneously renoprotective and cardioprotective, even without the presence of gout. Risk reductions on the order of 50% have been reported.
These results need validation in larger, multi-center trials, as well as determining optimal targets and treatment guidelines.
A lower Na diet has been suggested for CKD patients, and may help reduce proteinuria, but impact on progression has not been proven, and in heart failure, the role of a low sodium diet is being questioned (see Rothberg et al, J Gen Intern Med 25(10):1136–7, 2010). Proposed would be a randomized study in proteinuric diabetic CKD patients with target dietary Na of 1.5 vs. 3.0 g/day, with endpoints being 50% reduction in ...more »
A lower Na diet has been suggested for CKD patients, and may help reduce proteinuria, but impact on progression has not been proven, and in heart failure, the role of a low sodium diet is being questioned (see Rothberg et al, J Gen Intern Med 25(10):1136–7, 2010).
Proposed would be a randomized study in proteinuric diabetic CKD patients with target dietary Na of 1.5 vs. 3.0 g/day, with endpoints being 50% reduction in estimated cystatin GFR or dialysis/transplantation.
« less full details »
Patients with progressive CKD (diabetic and non-diabetic) benefit from aggressive treatment that improves control of its antecedents, such as poor control of blood pressure, blood glucose, lipid profiles, etc. Some multifactorial interventions have been effective (most notably, the Steno2 Study) but none have been widely translated to populations or conducted in a diverse US population. Telehealth approaches may help ...more »
Patients with progressive CKD (diabetic and non-diabetic) benefit from aggressive treatment that improves control of its antecedents, such as poor control of blood pressure, blood glucose, lipid profiles, etc. Some multifactorial interventions have been effective (most notably, the Steno2 Study) but none have been widely translated to populations or conducted in a diverse US population. Telehealth approaches may help overcome barriers to implementing efficacy studies in the US while allowing a scalable solution for translation to large populations (T2) if results are favorable.
« less full details »
Theoretical grounds suggest that direct renin inhibitors (Aliskiren) may be superior at slowing CKD progression compared to ACE-inhibitors or ARB, and is supported by some animal studies. Renoprotective effect in humans has been demonstrated, but whether this represents "superiority" remains an unanswered question. Larger trials, including head-to-head comparisons are needed to determine whether direct renin inhibition ...more »
Theoretical grounds suggest that direct renin inhibitors (Aliskiren) may be superior at slowing CKD progression compared to ACE-inhibitors or ARB, and is supported by some animal studies. Renoprotective effect in humans has been demonstrated, but whether this represents "superiority" remains an unanswered question.
Larger trials, including head-to-head comparisons are needed to determine whether direct renin inhibition provides superior protection against CKD progression, or might replace or supplant ACE/ARB as the standard of care.
« less full details »